FDA Approves Duloxetine Delayed-Release Capsules for MDD and GADFDA approves higher dose duloxetine capsules for depression and anxiety.

FDA Published August 21, 2026 DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider using this product only for maintenance after titration with another duloxetine product; do not initiate therapy with it.

The FDA has approved duloxetine delayed-release capsules (80 mg, 90 mg, and 120 mg) for the treatment of major depressive disorder (MDD) in adults and generalized anxiety disorder (GAD) in adults and pediatric patients aged 7 years and older. This approval provides a higher-strength formulation of the serotonin and norepinephrine reuptake inhibitor (SNRI) for patients already stabilized on lower doses of duloxetine. The product is not intended for initial therapy; clinicians must use another duloxetine product for starting treatment and dose titration.

For MDD, the recommended doses are 80 mg, 90 mg, or 120 mg once daily, while for GAD, the recommended doses are 90 mg or 120 mg once daily. The maximum studied dose is 120 mg per day. The label notes that doses above 60 mg per day have not been shown to confer additional benefit, but some patients may require higher doses. The approval is based on the established efficacy of duloxetine, though specific clinical trial data for this formulation were not included in the label.

Clinicians should be aware that this product is designed for patients who have been receiving at least 60 mg per day of another duloxetine product for one to two weeks, depending on the indication. The capsules must be swallowed whole and taken on an empty stomach. This approval offers an option for patients requiring higher maintenance doses without the need for multiple capsules.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI). The exact mechanism of action is not fully described in the label, but it is thought to potentiate serotonergic and noradrenergic activity in the central nervous system.

Indication & Patient Population

Duloxetine Delayed-Release Capsules are indicated for the treatment of: - Major depressive disorder (MDD) in adults - Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older

Dosing & Administration

- Do not initiate treatment with this product. Use another duloxetine delayed-release capsule product for initial dosage, titration, and doses below 80 mg per day. - Administer once daily on an empty stomach (at least one hour before or two hours after a meal). Swallow whole; do not open, chew, or crush. Do not sprinkle contents on food or mix with liquids. - MDD: Administer 80 mg, 90 mg, or 120 mg once daily. Periodically reassess for appropriate dosing. Maximum dosage is 120 mg once daily. - GAD (adults less than 65 years): Administer 90 mg or 120 mg once daily. For geriatric patients and pediatric patients 7 to 17 years, administer 90 mg or 120 mg once daily. Periodically reassess. Maximum dosage is 120 mg once daily. - When discontinuing, reduce dose gradually whenever possible. Gradual reduction will require use of another duloxetine product. - If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double the dose.

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

- Avoid use in patients with chronic liver disease or cirrhosis. - Avoid use in patients with severe renal impairment. - The label references Warnings and Precautions sections (e.g., 5.13) but does not provide full details in the provided text.

Place in Therapy

This product provides higher-strength duloxetine capsules for maintenance treatment in patients already stabilized on lower doses. It is not for initial therapy. It may be used for MDD and GAD when doses above 60 mg per day are considered, though the label notes no additional benefit has been demonstrated for doses above 60 mg. Clinicians should follow the specific titration and administration instructions.

The U.S. Food and Drug Administration (FDA) has approved a new higher strength version of the medicine duloxetine. This medicine is used to treat major depressive disorder (MDD) in adults and generalized anxiety disorder (GAD) in adults and children aged 7 and older. The new capsules come in strengths of 80 mg, 90 mg, and 120 mg. They are meant for people who are already taking a lower dose of duloxetine and need a higher maintenance dose.

This approval is not for people who are just starting treatment. Doctors must use a different duloxetine product to start the medicine and adjust the dose. The new capsules are for patients who have been taking at least 60 mg per day of another duloxetine product for one to two weeks. The capsules must be swallowed whole and taken on an empty stomach.

The approval is based on the known effectiveness of duloxetine. However, the label notes that doses above 60 mg per day have not been shown to give extra benefit, but some patients may need higher doses. This new option means patients who need higher doses might take fewer capsules.

If you or a loved one are taking duloxetine, talk to your doctor about whether this new strength is right for you. Do not change your dose or switch products on your own. Your doctor can help you decide based on your specific needs.

What this means for you:

This new higher dose duloxetine is for patients already on lower doses; talk to your doctor.

Study Details

Study typeFda approval

PublishedFeb 2026

View Original Abstract ↓

1 INDICATIONS AND USAGE Duloxetine Delayed-Release Capsules are indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Duloxetine Delayed-Release Capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 )

FDA Approves Duloxetine Delayed-Release Capsules for MDD and GADFDA approves higher dose duloxetine capsules for depression and anxiety.

Study Details

PETRUSHKA decision-support tool reduced treatment discontinuation and improved symptoms in major depressive disorder

The Algorithm That Helps Doctors Pick the Right Antidepressant for You

Clinical research that matters. Delivered to your inbox.

FDA Approves Duloxetine Delayed-Release Capsules for MDD and GADFDA approves higher dose duloxetine capsules for depression and anxiety.

Study Details

PETRUSHKA decision-support tool reduced treatment discontinuation and improved symptoms in major depressive disorder

The Algorithm That Helps Doctors Pick the Right Antidepressant for You

Clinical research that matters. Delivered to your inbox.

Related in Psychiatry

From Other Specialties